Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Product information and disease descriptionProduct descriptionProduct information

Product comparison

12 evidence topics · 11 sources

FDA-approved pharmacotherapies for GAD in adults

“Escitalopram has been approved by the FDA for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms [36–38] and was the first FDA-approved antidepressant for the treatment of GAD in this age group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Buspirone, a non-benzodiazepine anxiolytic and 5-HT1A receptor agonist, is approved for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Prescriber intent to administer DT120 compared with esketamine: company market research
Response of high-priority GAD prescribersDT120 ODTEsketamine
Prescribe and administer the treatment in own practice“51%”“26%”
Refer out (for DT120, the treatment; for esketamine, for esketamine)“40%”“61%”
Only discuss if a patient raises it (DT120), or refer out for evaluation without specifying esketamine“9%”“14%”
Other psychedelic and serotonergic agents in development for GAD and depressive disorders, as listed by the company

“A number of companies are developing product candidates with similar mechanisms to DT120 that are intended for the treatment of anxiety and depressive disorders, including AtaiBeckley Inc. (“AtaiBeckley”), Compass Pathways plc (“Compass”), GH Research (“GH Research”), Cybin, Inc. doing business as Helus Pharma (“Helus”), Johnson & Johnson (“J&J”), Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) and others.” (opens the source at this quote in a new tab)

“Helus is currently evaluating HLP004 (a serotonin receptor agonist) in a Phase 2 trial for the treatment of GAD, with an anticipated topline data readout in the first quarter of 2026. In addition, Otsuka is currently conducting a Phase 2/3 clinical trial of ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of GAD and MDD.” (opens the source at this quote in a new tab)

“Intra-Cellular Therapies, now a part of J&J (“Intra-Cellular”), is currently developing multiple product candidates that are in various phases of development for the treatment of GAD and MDD, including CAPLYTA (lumateperone), which was approved by the FDA in November 2025 as an adjunctive treatment for adults with MDD, and ITI-1284 ODT-SL for GAD.” (opens the source at this quote in a new tab)

“Compass is developing COMP360 (a proprietary formulation of psilocybin) that is in Phase 3 clinical trials for the treatment of TRD in adults and is being studied in other psychiatric indications (anorexia nervosa and post-traumatic stress disorder).” (opens the source at this quote in a new tab)

“There are also many other public and private companies developing therapeutics from the psychedelic drug class at various stages of development, including certain short-acting psychedelic drugs.” (opens the source at this quote in a new tab)

Head-to-head clinical comparison of DT120 with an approved GAD treatment

No evidence found.